评估匹杉琼联合奥妥珠单抗治疗复发侵袭性淋巴瘤的II期试验:前瞻性多中心GOAL试验最终结果
GOAL试验前瞻性评估匹杉琼联合奥妥珠单抗最多6个周期治疗复发或难治性弥漫大B细胞淋巴瘤(DLBCL)的疗效,主要终点为总缓解率(ORR)。68例可评估患者中位年龄75岁,中位既往治疗线数3线,ORR为35.3%(可评估患者40%,完全缓解16.6%),中位无进展生存期(PFS)2.8个月、总生存期(OS)8个月;非生发中心B细胞样(non-GCB)表型患者OS优于GCB型(中位OS未达到 vs 5.2个月)。试验未达到主要终点。
要点
- 匹杉琼联合奥妥珠单抗治疗复发/难治性DLBCL的ORR为35.3%,可评估患者ORR为40%,完全缓解率16.6%。
- 中位PFS为2.8个月,中位OS为8个月;non-GCB表型患者中位OS未达到,优于GCB型的5.2个月。
- 既往仅1线治疗患者PFS未达到,优于后续线数患者的2.5个月;主要非血液学毒性为感染(28%)。
核心结论
- 匹杉琼联合奥妥珠单抗显示出临床活性,部分患者获得长期缓解,但试验未达到主要终点。
研究设计与样本
- 前瞻性、多中心II期GOAL试验,评估匹杉琼联合奥妥珠单抗最多6个周期治疗复发或难治性DLBCL患者,主要终点为ORR。
- 共68例患者可评估,中位年龄75岁,中位既往治疗线数3线(范围1-10线);52例(76.5%)诊断为DLBCL,16例(23.5%)为转化性惰性淋巴瘤或滤泡性淋巴瘤(FL)IIIB。
主要发现
- 全部患者ORR为35.3%,可评估患者ORR为40%,完全缓解率16.6%。
- 中位PFS为2.8个月,中位OS为8个月。
- non-GCB表型患者中位OS未达到,GCB表型患者中位OS为5.2个月。
- 既往1线治疗患者PFS未达到,后续线数治疗患者PFS为2.5个月。
- 疾病进展是提前终止治疗的主要原因;不良事件主要为血液学毒性,最常见的非血液学毒性为感染(28%),联合治疗未出现意外不良事件。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The prognosis of patients with relapsed diffuse large B-cell lymphoma (DLBCL) remains poor with current options. Here we prospectively evaluated the combination of pixantrone with obinutuzumab for up to six cycles for patients with relapsed or refractory DLBCL. Overall response rate (ORR) was the primary end-point. Sixty-eight patients were evaluated, median age was 75 years, median number of prior lines was three (range 1-10), 52 patients (76.5%) were diagnosed with DLBCL and 16 (23.5%) patients had transformed indolent lymphoma or follicular lymphoma (FL) IIIB. ORR was 35.3% for all and 40% for evaluable patients (16.6% complete response), median progression-free survival (PFS) and overall survival (OS) were 2.8 months and 8 months, respectively. Analysis of the cell of origin revealed a superior course for patients with non-GCB (germinal centre B-cell-like) phenotype [median OS not reached (n.r.) vs 5.2 months]. Patients with one prior line had an improved outcome over patients treated in later lines (PFS n.r. vs 2.5 months). Disease progression was the main reason for premature termination. Adverse events were mainly haematologic. The combination treatment revealed no unexpected adverse events. Most relevant non-haematologic toxicity was infection in 28% of patients. In summary, pixantrone-obinutuzumab showed clinical activity with sometimes long-term remission; however, the trial failed to meet its primary end-point.
引用
- Hess G, Hüttmann A, Witzens-Harig M, et al. A phase II trial to evaluate the combination of pixantrone and obinutuzumab for patients with relapsed aggressive lymphoma: Final results of the prospective, multicentre GOAL trial. Br J Haematol. 2022. PMID: 35362552. doi:10.1111/bjh.18161
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。